Citations 2
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
Plesner, Torben , Kumar, Shaji , Hulin, Cyrille , Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand , Pei, Huiling , Kaila, S., Matt, K., Gries, Katharine S. , Carson, Robin, Borgsten, F., Facon, Thierry T.F. , Usmani, Saad Z. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Karlin, Lionel , Chari, Ajai , Gupta, Neeraj , Matt, K., Weisel, Katja C , Perrot, Aurore
HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 18-19
PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
Chinaeke, E., Gupta, Niodita, Fu, Alex Z. , Ran, T., Kaila, S., Fonseca, Rodrigo , Ran, T.
HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1874-1875